VERTEX PHARMACEUTICALS INC / MA

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. The company operates in the pharmaceutical industry, which is characterized by extensive research efforts, rapid technological progress, and intense competition. Vertex has approved medicines for cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and acute pain, and continues to advance next-generation clinical and research programs in these areas. Its mid- and late-stage clinical pipeline includes programs across a range of modalities in additional serious diseases, including IgA nephropathy, APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, autosomal dominant polycystic kidney disease, and myotonic dystrophy type 1.

Vertex's competitive positioning is built on its leadership in CF, where its five CF medicines are being used by nearly three quarters of the approximately 97,000 ¹ people with CF in the U.S., Europe, Australia, and Canada. The company estimates there are approximately 112,000 ² people with CF in all target markets. In SCD and TDT, Vertex estimates approximately 60,000 ³ people with severe SCD or TDT are or could become eligible for CASGEVY in approved geographies. For acute pain, it is estimated that over 80 million ⁴ people are prescribed a medicine for acute pain every year in the U.S. The company faces competition from many public and private companies, including pharmaceutical and biotechnology companies, academic institutions, and other research organizations, some of which have substantially greater financial, technical, sales and marketing, and human resources. Vertex believes its long-term competitive success depends on discovering and developing or acquiring transformative medicines and continuously improving productivity.

Vertex generates revenue primarily through the sale of its approved medicines, which are sold to a limited number of specialty pharmacy and specialty distributors globally, as well as to certain major wholesalers in the U.S. Outside the U.S., sales are generated primarily through distributor arrangements and to retail pharmacies, as well as to hospitals and clinics. The company also generates other revenues from upfront payments received from out-licensing agreements. Vertex's core strategy is to discover, develop, and commercialize innovative medicines by combining transformative advances in the understanding of human disease and the science of therapeutics, focusing on validated targets that address causal human biology, predictive lab assays and clinical biomarkers, rapid paths to registration and approval, and product candidates that hold the potential for transformative patient benefit. The company aims to serially innovate in its disease areas of interest and follow first-in-class therapies with potential best-in-class candidates.

Vertex's marketed products include five CF medicines: ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), approved in 2024 for patients 6 years of age and older; TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), approved in 2019 for patients 2 years of age and older; SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), approved in 2018 for patients 6 years of age and older; ORKAMBI (lumacaftor/ivacaftor), approved in 2015 for patients 1 year of age and older; and KALYDECO (ivacaftor), approved in 2012 for patients 1 month of age and older. For SCD and TDT, CASGEVY (exagamglogene autotemcel) was approved in 2023 for patients 12 years of age and older. For acute pain, JOURNAVX (suzetrigine) was approved in 2025 for adults. In 2025, TRIKAFTA/KAFTRIO generated net product revenues of $10,312.7 million ⁵, ALYFTREK generated $837.8 million ⁶, and other product revenues, including CASGEVY at $115.8 million ⁷ and JOURNAVX at $59.6 million ⁸, totaled $820.1 million ⁹. Other revenues were $30.7 million ¹⁰, which included $20.6 million ¹¹ and $10.0 million ¹² related to upfront payments from agreements with Ono and Zai, respectively.

Significant operational developments during the period include the acquisition of Alpine Immune Sciences, Inc. in 2024 for approximately $5.0 billion ¹³, which added povetacicept, a dual inhibitor of BAFF and APRIL, to the pipeline. In 2025, Vertex entered into out-licensing agreements with Zai Lab Limited and Ono Pharmaceuticals Co., Ltd for the development and commercialization of povetacicept in certain Asian markets. The company also initiated a share repurchase program in May 2025, authorizing up to $4.0 billion ¹⁴ of common stock, of which $618.5 million ¹⁵ had been repurchased as of December 31, 2025. In the first quarter of 2025, Vertex recorded a full intangible asset impairment charge of $379.0 million ¹⁶ associated with the VX-264 program, which was discontinued after not meeting its efficacy endpoint. Additionally, on October 10, 2025, Royalty Pharma plc initiated a confidential arbitration alleging the royalty burden on ALYFTREK is approximately 8% ¹⁷, while Vertex's position is that the royalty burden is 4% ¹⁸.

In 2025, total revenues increased to $12,001.3 million ¹⁹ compared to $11,020.1 million ²⁰ in 2024, a 9% increase, primarily due to continued strong demand for TRIKAFTA/KAFTRIO and contributions from launches of ALYFTREK, JOURNAVX, and CASGEVY. Net product revenues were $11,970.6 million ²¹ in 2025 versus $11,020.1 million ²² in 2024. Cost of sales as a percentage of net product revenues decreased from 13.9% ²³ in 2024 to 13.8% ²⁴ in 2025. Total research and development (R&D) and selling, general and administrative (SG&A) expenses increased to $5,662.6 million ²⁵ in 2025 from $5,094.6 million ²⁶ in 2024. Acquired in-process research and development expenses (AIPR&D) were $133.0 million ²⁷ in 2025 compared to $4,628.4 million ²⁸ in 2024, which included $4.4 billion ²⁹ from the Alpine acquisition. Net income was $3,940.0 million ³⁰ in 2025 compared to a net loss of $248.6 million ³¹ in 2024. Total cash, cash equivalents and marketable securities increased to $12,320.4 million ³² as of December 31, 2025 from $11,223.8 million ³³ as of December 31, 2024.

A major growth vector is the continued expansion of the CF business, particularly through the transition of patients to ALYFTREK, which has the benefit of a once-daily dosing regimen and demonstrated non-inferiority to TRIKAFTA in ppFEV1. Vertex expects that the majority of people with CF will transition to ALYFTREK over time. The company is also pursuing label expansions for younger age groups: it expects to begin submissions for global regulatory approvals for TRIKAFTA in children one year to less than two years of age in the first half of 2026, and expects to submit for approval for ALYFTREK in children 2 to 5 years of age in the first half of 2026. Additionally, Vertex initiated a pivotal trial evaluating ALYFTREK in children one to less than two years of age. The company estimates that nearly 95% ³⁴ of people with CF could benefit from its five approved medicines.

Another significant growth vector is the advancement of the pipeline in non-CF diseases. For IgA nephropathy (IgAN), Vertex completed enrollment in the Phase 3 clinical trial of povetacicept and submitted the first module of the rolling BLA in the fourth quarter of 2025, expecting to complete the submission for potential accelerated approval in the U.S. in the first half of 2026. For APOL1-mediated kidney disease (AMKD), Vertex completed enrollment of the interim analysis cohort of the Phase 2/3 clinical trial of inaxaplin and expects to share data from the interim analysis in late 2026 or early 2027. For peripheral neuropathic pain, Vertex is evaluating suzetrigine in two Phase 3 clinical trials for diabetic peripheral neuropathy (DPN) and expects to complete enrollment in both by the end of 2026. For type 1 diabetes (T1D), Vertex completed enrollment in the Phase 1/2/3 clinical trial of zimislecel but has temporarily postponed completion of dosing pending an internal manufacturing analysis. For primary membranous nephropathy (pMN), Vertex expects to complete the Phase 2 portion of the adaptive Phase 2/3 pivotal trial of povetacicept and initiate the Phase 3 portion in mid-2026. The company also expects to initiate a placebo-controlled Phase 2 proof-of-concept clinical trial of povetacicept for generalized myasthenia gravis (gMG) in the first half of 2026.

Vertex expects its cost of sales as a percentage of net product revenues to increase in 2026 due to a higher proportion of products outside of CF, which currently have greater manufacturing costs relative to their net product revenue contributions, and continued investments in efficient manufacturing and delivery processes. The company expects its selling, general and administrative expenses to continue to increase in 2026 as it expands the commercialization of JOURNAVX, prepares for the anticipated launch of povetacicept for IgAN, and further invests in infrastructure to scale the organization. Research and development expenses are expected to continue to increase due to advancing pipeline programs, including T1D programs.

Vertex is focused on ensuring the stability of the supply chains for its current products, including CF medicines, CASGEVY, and JOURNAVX, and for its pipeline programs. The company is investing in expanding and strengthening its manufacturing infrastructure and capabilities, such as cGMP clinical manufacturing, both independently and through third-party networks, to develop and commercialize biologics and cell and genetic therapies. Vertex has established cell therapy manufacturing capabilities at its facilities in the Boston area to supply clinical and potentially commercial quantities of cell therapies, including plans to utilize its own manufacturing capabilities for additional commercial supply of CASGEVY. The company also has a strategic agreement with Lonza to support the manufacture of T1D cell therapy product candidates, pursuant to which they are building a 130,000 ³⁵ square foot dedicated new facility in New Hampshire. Vertex is also constructing the second building of its Leiden Campus (Leiden II), which will include approximately 348,000 ³⁶ square feet of office and laboratory space and is expected to be operational in late 2026.

Vertex's capital allocation priorities include continued investment in R&D, with research and development expenses totaling $3,909.5 million ³⁷ in 2025. The company expects development expenses to continue to increase in 2026. Capital expenditures are not explicitly guided, but investing activities included net purchases of available-for-sale debt securities and purchases of property and equipment. In May 2025, the Board of Directors approved a share repurchase program authorizing up to $4.0 billion ³⁸ of common stock, of which $618.5 million ³⁹ had been repurchased as of December 31, 2025, leaving $3,381.5 million ⁴⁰ remaining authorization. Vertex has never paid any cash dividends on its common stock and does not anticipate paying any in the foreseeable future.

Vertex faces structural headwinds from pricing and reimbursement pressures. The company notes that the U.S. federal government and state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, value-based and reference pricing, compulsory licensing, and mandatory substitution with generic products. In the U.S., the Inflation Reduction Act (IRA) established a Medicare Drug Price Negotiation Program, and while certain Vertex drugs are currently excluded, other elements of the IRA may have a material impact. State Prescription Drug Affordability Boards (PDABs), including in Colorado, have selected TRIKAFTA for affordability review. Outside the U.S., many governments are introducing new legislation focused on cost containment measures, which could lead to lower prices, rebates, or other forms of discounts or special taxes. Vertex also faces headwinds from competition, noting that competing products may be more effective, safer, more effectively marketed, or have lower prices, and that the introduction of new products or technologies results in increased competition and pricing pressure.

Vertex faces execution risks related to its complex manufacturing and supply chain, particularly for biologics and cell and genetic therapies. The company depends on a global network of third parties, including some based in China, and any disruption could result in shipment delays, inventory shortages, or other interruptions. The manufacturing process for CASGEVY is particularly complex, involving multiple steps from cell collection to infusion, and the cost of manufacturing CASGEVY as a percentage of revenue is significantly higher than for CF medicines. Vertex also faces risks related to its reliance on third-party relationships for critical activities such as clinical trial management, manufacturing, and distribution. Additionally, the company notes that its business development strategy, including strategic transactions and collaborations, may not be successful, and there may be delays or failures in realizing anticipated benefits.

Vertex's business is substantially dependent on the success of its CF medicines, which have historically generated substantially all net product revenues; any inability to sustain or increase these revenues due to competition, manufacturing disruptions, or safety issues would materially harm the business. The company faces significant pricing and reimbursement pressures, including from U.S. legislation like the Inflation Reduction Act and state Prescription Drug Affordability Boards, which could limit prices or access to products. For example, the Colorado PDAB selected TRIKAFTA for an affordability review. Vertex also faces substantial risk from the complex and costly manufacturing and supply chain for its products, particularly for CASGEVY, where the cost of manufacturing as a percentage of revenue is significantly higher than for CF medicines, and any disruption could negatively affect patients and reduce revenues. Additionally, the company's success depends on its ability to develop and commercialize additional medicines, and product development is highly uncertain; clinical trials may fail to establish safety and efficacy, as occurred with VX-264, which resulted in a $379.0 million ⁴¹ impairment charge. Finally, Vertex is subject to extensive government regulation, and failure to comply could result in fines, penalties, or withdrawal of product approvals.

Management's tone in the filing is forward-looking and emphasizes the company's commitment to serial innovation and advancing a diversified pipeline. Key themes include the continued growth of the CF business through ALYFTREK and label expansions, the commercial launches of JOURNAVX and CASGEVY, and the advancement of five pivotal programs across multiple disease areas. Management emphasizes that the core strategy is to discover, develop, and commercialize innovative medicines by combining transformative advances in the understanding of human disease and the science of therapeutics. The strategic priorities emphasized for the period ahead include: completing the submission for potential accelerated approval of povetacicept in IgAN in the first half of 2026; sharing data from the interim analysis of the inaxaplin Phase 2/3 trial in AMKD in late 2026 or early 2027; completing enrollment in both Phase 3 clinical trials of suzetrigine in DPN by the end of 2026; and continuing to expand access for CASGEVY and JOURNAVX. Management also notes the expectation that the majority of people with CF will transition to ALYFTREK over time and that total revenues are expected to increase in 2026 due to continued growth of CF product revenues and increased contributions from CASGEVY and JOURNAVX.